Raoul S. Concepcion, MD, FACS

Raoul S. Concepcion, MD, FACS

The Comprehensive Prostate Center

Nashville, Tennessee

Raoul S. Concepcion, MD, is the current Director of The Comprehensive Prostate Center in Nashville, Tennessee, as well as the Chief Urologic Officer for Integra Connect in West Palm Beach, Florida. He was a resident in General Surgery and Urology at Vanderbilt University from 1984-1990, and later served as a Clinical Associate Professor of Urology there. Dr. Concepcion’s clinical interests revolve around advanced prostate and bladder cancer management. He is a past President of LUGPA. Along with two other urologists, founded CUSP, a urologic research consortium in the United States. Additionally, he is an advisor or speaker for many companies, including Dendreon, Pfizer, Astellas, Amgen, Cellay, and Janssen, and is the current editor for Urologists in Cancer Care.

Articles by Raoul S. Concepcion, MD, FACS

The Effect of Local Antibiogram-Based Augmented Antibiotic Prophylaxis on Infection-Related Complications Following Prostate Biopsy

Raoul S. Concepcion, MD, FACS, and E. David Crawford, MD, discuss a recent study Dr. Concepcion was involved with that looked at antibiotic-augmented prophylaxis based on local antibiograms as a method of reducing infections from prostate biopsies. They discuss the design and rationale of the study and methods for administering the prophylaxis, as well as the results, which showed a 53% reduction in infectious complications compared to historical data.

Read More

New Considerations for Oligometastatic Prostate Cancer

Raoul S. Concepcion, MD, FACS, discusses the management of patients with oligometastatic prostate cancer. Currently, there is no standard definition of what defines oligometastatic.  Additionally, questions remain about the handling of the primary tumor in this setting, as well as whether therapy directed at the primary has a long term benefit in overall survival.

Read More

AR-V7 Predicts Response in CRPC

Raoul S. Concepcion, MD, FACS, emphasizes the need for more effective biomarkers when determining adequate treatment for patients with castrate-resistant prostate cancer (CRPC). Concurrently, he compares the findings of studies exploring various options, including the AR-V7 splice variant.

Read More

Join the GRU Community

- Why Join? -